MASSDEVICE ON CALL — GI Dynamics (ASX:GID) EndoBarrier gastrointestinal implant proved effective in mildly obese and overweight Type II diabetics, according to a new study.

In a non-randomized, single-arm study of 20 patients with Type II diabetes, the EndoBarrier implant lowered blood glucose levels in more than half and led to a statically significant decrease in total body weight loss of 9.4%, according to a press release.

"Our data point to a substantial improvement in glycemic control and other metabolic parameters even among overweight – but not severely obese – diabetic patients during EndoBarrier Therapy," researcher Dr. Ricardo Cohen said in prepared remarks. "These are promising data and suggest that EndoBarrier may play a valuable role for overweight patients struggling to control their diabetes and lose weight."

 Can docs overcome own biases when evaluating conflicts of interest?
A new study recommends 3rd-party conflict of interest policy-making after finding that physicians are biased when evaluating policies.  
Read more

 Retired Massachusetts teacher gets New England’s 1st artificial heart
Retired high school teacher Jim Carelli is the 1st patient in New England to receive life support from an artificial heart device while awaiting a heart transplant.
Read more

 Masimo’s pulse co-oximetry devices speed carbon monoxide poisoning evaluation and treatment
Masimo’s (NSDQ:MASI) Rainbow pulse co-oximetry devices had a "significantly shorter" time to carbon monoxide poisoning evaluation and treatment, according to a new study.
Read more

 Pelvic slings have pros and cons, study says
Pelvic slings used to treat incontinence in women reduce symptoms but increase side effects, researchers say.
Read more